These effects, along with a former report showing that a little-molecule ACKR3 agonist CCX771 reveals anxiolytic-like conduct in mice,2 assist the thought of targeting ACKR3 as a singular method to modulate the opioid procedure, which could open up new therapeutic avenues for opioid-connected Di